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Opinion statement
IgE-mediated allergies today affect up to 30 % of the population in industrialized
countries. Allergen immunotherapy is the only disease-modifying treatment option
with a long-term effect. However, very few patients (G5 %) choose immunotherapy,
due to the long treatment duration (between 3–5 years) and possible local and system-
ic allergic side effects of the allergen administrations. The latter occur when an aller-
gen accidentally reaches the blood circulation. Therefore, the ideal application route
for allergen immunotherapy should be characterized by two hallmarks: firstly, by a high
number of potent antigen-presenting cells, which enhance efficacy and thus shorten
treatment duration. Secondly, the allergen administration site is ideally non-
vascularized, so that inadvertent systemic distribution of the allergen and conse-
quent systemic allergic side effects are minimized. The epidermis contains high
numbers of potent antigen-presenting Langerhans cells and, as an epithelium, is
non-vascularized. Therefore, the epidermis represents an interesting administration
route. Historical evidence for the clinical efficacy of epicutaneous allergy immuno-
therapy (EPIT) has now been strengthened by a number of recent double-blinded
placebo-controlled clinical trials performed by independent groups. We review the
immunological rationale, history and clinical experience with epicutaneous allergy
immunotherapy.
Introduction
With a current prevalence of up to 30% in industrialized
countries, IgE-mediated allergies have become an impor-
tant socioeconomic burden. Symptomatic treatment
with antihistamines and corticosteroids can efficiently
ameliorate IgE-mediated symptoms [1], but does not
stop progression of the underlying allergy. The only dis-
ease-modifying treatment is allergen immunotherapy
(AIT) [1, 2]. Subcutaneous allergen-specific immuno-
therapy (SCIT) was introduced more than a century
ago by Leonard Noon [3], but has two major disadvan-
tages: it is time-consuming, as it requires 30–70 visits
to a medical practice, and subcutaneous allergen injec-
tions are associated with local and systemic allergic side
effects [4–6]. These twomain drawbacksmay potentially
be resolved by the following strategies.
First, to reduce the number of injections, immunoge-
nicity of the allergen administration must be enhanced.
This may theoretically be achieved (1) by increasing the
allergen dose. While a dose effect in AIT is evident [7,
8], allergic side effects prohibit significant dose increases.
Use of hypoallergenic allergens by chemical modification
to allergoids [9], by recombinant modification [10] or by
using non–IgE-binding peptides [11, 12, 13••], may per-
mit increased allergen doses, but could reduce allergen
immunogenicity. A reduction of injection numbers may
also be achieved (2) by replacing the classical adjuvant al-
um,which is considered to actually favour a Th2 response,
with a Th1-promoting adjuvant such as the Toll-like re-
ceptor (TLR) ligands CpG [14•] or MPLA [15–17]. The
number of injections may also be reduced (3) by allergen
delivery via a route characterized by a high density of an-
tigen-presenting cells. These are present at highest density
in secondary lymphatic organs such as lymph nodes, and
indeed, when administered intralymphatically, the num-
ber of allergen injections could be reduced to only three
[18•, 19•, 20].
Second, to improve the safety of AIT, inadvertent al-
lergen delivery to the blood vasculature must be
avoided. Ideally, the allergen should be delivered to a
non-vascularized tissue. In certain ways, sublingual al-
lergy immunotherapy (SLIT) fulfils this criterion, as
the allergen is delivered to the oral mucosa, which is
covered by a multi-layered epithelium. Despite diffu-
sion of the allergen down into deeper layers containing
mast cells, which are responsible for the frequently ob-
served local oral side effects [7, 21], SLIT is considered
very safe with respect to systemic allergic side effects
[7, 21]. Apparently, diffusion into a vascularized layer
is less risky than injection into a vascularized layer.
The same should be true for epicutaneous allergy im-
munotherapy (EPIT), where an allergen is administered
to the non-vascularized epidermis. However, as an ad-
vantage of EPIT over SLIT, keratinocytes can additional-
ly be activated by physical irritation, e.g., abrasion or
adhesive tape stripping, or by adding adjuvants [22].
Epithelial damage increases keratinocyte expression of
additional molecules such as IL-1α, IL-6 and TNF-α,
skewing the immune response toward a Th1-type re-
sponse [23]. Such activation of keratinocytes is impor-
tant for creating a pro-inflammatory environment
with enhanced activation of Langerhans cells.
Hence, EPIT has the potential not only to reduce
side effects by minimizing allergen penetration to
the vasculature, but also to shorten treatment duration
by increasing immunogenicity of the administered al-
lergen formulation.
Potential application fields of EPIT
Vaccination started with epicutaneous immunization, when Edward Jenner
applied cow pox virus to scarified human skin [24]. Having then been for-
gotten for a long time, epicutaneous vaccination had its revival at the be-
ginning of the twenty-first century, driven by the increasing interest in novel
needle-free vaccination routes [25, 26]. Epicutaneous vaccination against
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Escherichia coli–induced traveller’s diarrhoea [27••] was the first step. Animal
models have so far shown successful vaccination against infection with
Helicobacter pylori [28], influenza virus [29] and diphtheria toxin [30]. The
protective mechanism in all of these applications relies on induction of
humoral immunity dominated by IgG1 and IgA. Studies testing epicutaneous
vaccination against HIV also found induction of mucosal cytotoxic T cells
together with secretion of mucosal antibodies [31]. Another field of appli-
cation is cancer immunotherapy. Several groups achieved promising results
with epicutaneous immunotherapy against skin cancer based on induction of
potent CD8+ T cell responses [32, 33]. Not only has EPIT been demonstrated
to induce effector T cell responses, but also suppressive T cell responses when
EPIT was used to inhibit experimental allergic encephalomyelitis [34, 35].
History of EPIT in allergy treatment
EPIT as a treatment for allergies was introduced surprisingly early. In 1917,
Besredka showed that EPIT was able to induce specific antibodies [36••], and
the first case study on successful epicutaneous allergy immunotherapy was
reported in 1921 by Vallery-Radot, who found that allergen administration
onto scarified skin reduced systemic allergic symptoms in patients allergic to
horses [37•].
A decade later, when the risk of suffering a “pollen shock” during allergen
immunotherapy was recognized to be a considerable danger of subcutane-
ously administering allergen to highly sensitized patients, a similar
method—called intradermal allergen specific immunotherapy—received at-
tention [38, 39]. Based on the observation that hay-fever patients occasion-
ally experienced symptom amelioration after “intradermal pollen tests”, E.
W. Phillips started to treat highly sensitive patients as well as patients
requesting co-seasonal treatment by administration of pollen extract [39].
Strikingly, such intradermal allergy immunotherapy proved to be both safe
and highly efficacious, leading to symptom relief after administration of only
three doses [39]. At the same time, M. A. Ramirez treated patients allergic to
grass pollen with a method he called “cuti-vaccination”, which consisted of
administration of pollen extract onto scarified skin [36••]. Based on these
results, it was suggested in the 1930s that the subcutaneous route might not
be optimal for administration of AIT: “knowledge of the epidermis as an
immunologic organ is still meager … it may be theoretically possible that a
more effective desensitization may be attained by this route than by the
subcutaneous one” [38].
Between 1950 and 1960 French allergologists revisited EPIT [40, 41].
Pautrizel administered the allergen extract onto slightly rubbed epidermis.
Even though the reported results were excellent, a large number of applica-
tions were necessary until symptom relief was observed [40]. Blamoutier, in
contrast, applied the allergen drops onto heavily scarified skin [36••, 41]:
“On the proximal volar aspect of the lower arm, in a square area of 4×4 cm,
chessboard-like horizontal and vertical scratches are made with a needle....
These scratches should be superficial and not cause bleeding” [42]. Consis-
tently, allergic side effects were observed only rarely when allergen was ap-
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plied via the skin, and if they occurred nevertheless, these reactions were
always milder than under conventional SCIT [36••, 39–41]. These promising
results were supported by several studies performed in the subsequent years
all over Europe, from Switzerland [42, 43] to Portugal [44]. Overall, symp-
tom relief was obtained rapidly and allowed for co-seasonal treatment. The
reported treatment success rates of 80 % exceeded the success rates under
conventional SCIT [42]. Despite such successful results with the French
méthode de quadrillage cutané, reports on this promising administration route
disappeared into oblivion for almost half a century.
EPIT for aeroallegens
While there is strong scientific and historical evidence for EPIT in allergy
treatment, no double-blind placebo-controlled clinical trials existed, a
fact that led our group to revisit EPIT. Driven by the idea to find a
patient-convenient application route of AIT in order to increase its at-
tractiveness, and based on the good accessibility of the skin and its high
density of potent immune cells, our group performed three clinical trials
to test efficacy and safety of EPIT. In order to keep epithelial barrier
disruption minimal, we replaced skin scarification by adhesive tape
stripping [45]. Besides enhancing the penetration of allergens by re-
moving stratum corneum [46], repeated tape stripping also functions as a
“physical” adjuvant through activation of keratinocytes, which then se-
crete various pro-inflammatory cytokines (IL-1, IL-6, IL-8, TNF-α and
IFN-γ) favouring maturation and emigration of DCs to the draining
lymph nodes [47, 48]. Results of the first pilot trial revealed that patients
treated with a total of 12 patches containing pollen extract experienced
significant alleviation of hay fever symptoms compared to placebo-
treated patients. In line with the “historical” study results described
above, no severe systemic allergic reactions were reported. The only ad-
verse events observed were very mild local eczematous reactions under
the skin patch [45]. When looking at all 12 patch applications, mild
eczema was observed in 15 out of the 21 verum patients, whereas such
eczema was only seen in 5 out of the 15 placebo patients. When looking
at a single patch application, eczema under the patch, with a severity
score between 3 and 6 on a scale ranging from 0 to 18, was observed in
roughly half of the verum patients. In order to exclude partial
unblinding of the study by the occurrence of local adverse effects, we
had analysed whether or not the occurrence of eczema under the patch
correlated with symptom amelioration, but we could not find such a
correlation. Encouraged by these results, a second phase I/IIa trial in-
cluding a total of 132 grass pollen–allergic patients was initiated to find
the optimal treatment dose of EPIT. Enrolled patients were treated co-
seasonally with a total of six patches. We found a clear relationship
between the administered allergen dose and the clinical effect, with the
highest allergen dose leading to the most marked symptom improvement
[49•]. Also, we found a dose-dependence of the local adverse effects
where patches were applied, with pruritus being the most frequently
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reported adverse event, followed by eczema observed after patch re-
moval. Interestingly, with every subsequent patch application, there was
a reduction of local adverse events. After the sixth patch application,
only half as many local adverse events were reported. This reduction was
not explicable by local depletion of immune cells or degranulation of
mast cells, as each of the six patches was applied to a different area of
the arm. Therefore, the reduction of local adverse events is likely to be
explained by tolerance induction. A third clinical trial investigated the
immunological changes induced during EPIT and found an increase in
allergen-specific IgG4 [50]. Our results have meanwhile been confirmed
by an independent group that demonstrated efficacy and safety of EPIT
in grass pollen–allergic children. Hay fever symptoms, as well as the use
of antihistamines, were significantly reduced in the active treatment
group [51•].
Also, the results of intradermal allergy immunotherapy reported by W.
Philipp back in 1926 have meanwhile been indirectly confirmed in a dou-
ble-blind placebo-controlled trial by Rotiroti et al. [52••]. They found that
six low-dose intradermal injections with grass pollen extract, i.e., only 7 ng of
Phl p 5 per injection, strongly reduced the allergen-induced cutaneous late
response.
So far, there is no head-to-head comparison of EPIT to other routes of
administration, except in mouse models. Using the major grass pollen
allergen Phl p 5, EPIT was found in the mouse to be at least equivalent to
SLIT [53]. While EPIT and SLIT induced similar IgG2a levels and also led
to a similar reduction in IgE levels in sensitized mice, it was only EPIT
that led could significantly reduce eosinophil counts in the bronchoalve-
olar lavage (BAL) in the asthma model. Also in mice, we have compared
SCIT with EPIT using ovalbumin as the allergen. While EPIT without ad-
juvant was less immunogenic than SCIT, EPIT with an adjuvant was found
to be more immunogenic, so that EPIT and SCIT appeared comparable in
efficacy [22].
EPIT for food allergens
A clinical pilot trial to test clinical efficacy and safety of EPIT using the
Viaskin® EDS in children suffering from cow’s milk allergy showed a ten-
dency toward an increased cumulative tolerance dose after a three-month
treatment period, but missed statistical significance. Treatment was well
tolerated, with no systemic anaphylactic reactions, but a significant increase
of local eczematous skin reactions was observed [54••]. Such good safety
results are crucial, especially when considering the use of EPIT as treatment
option for food allergies for which conventional SCIT is impractical due to
an unacceptably high rate of anaphylactic reactions [55]. To substantiate
these early findings, and aiming to develop a definitive therapeutic op-
tion for food allergy patients, a phase I (NCT01170286) as well as a
phase II trial (NCT01197053) have recently been initiated with the ob-
jective to test treatment efficacy of EPIT with the Viaskin® EDS in peanut
allergy patients.
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Outlook
As there now exist several placebo-controlled double-blind clinical trials
confirming the efficacy of EPIT in allergy treatment [45, 49•, 51•, 52••,
56], there remains little doubt that this method works in principle. Our
clinical trial program has also shown that the allergen dose is an im-
portant efficacy parameter [49•]. The allergen dose used in skin patches
cannot readily be increased any further. We had already used 30 μg of
major grass pollen allergen Phl p 1, corresponding to 1 ml of the tenfold
concentration that is used for the skin prick solution. A higher concen-
tration would not only generate considerable cost of materials, but ap-
plication to any accidentally impaired skin barrier would increase the
risk for systemic allergic effects. Future research should therefore focus
on enhancing penetration of the stratum corneum into the viable layers
of the skin where Langerhans cells reside, and also on adjuvants suitable
for epicutaneous administration.
Methods for enhancing penetration across the skin barrier include (1)
hydration of the stratum corneum, which facilitates diffusion of hydro-
philic molecules. Any form of occlusion, such as the patches we [45,
49•] and others [51•] have used, hydrates the skin by accumulation of
sweat [54••, 57]. Also, a French group recently developed an alternative
form of EPIT based on allergen delivery to the intact skin using an oc-
clusive epidermal delivery system (Viaskin® EDS) [54••, 57, 58]. Initially
developed for diagnostic purposes as an alternative system to the con-
ventional Finn chamber used in atopy patch test [59], Viaskin® relies on
the ability to deliver whole protein molecules to the skin [57, 58].
Perspiration generated under an occlusive chamber dissolves the
lyophilised allergen protein loaded on the Viaskin® EDS [57, 58]. De-
livered via such EDS, proteins have been demonstrated to accumulate in
the stratum corneum, where they efficiently targets immune cells of the
superficial skin layer [60] that rapidly migrate to the draining lymph
nodes [57]. In murine studies, EPIT using the Viaskin® EDS showed ef-
ficacy equivalent to SCIT in preventing allergic airway reactions upon
inhalative allergen challenge [57]. Skin penetration may also be en-
hanced (2) by adding so called penetration enhancers, such as salicylic
acid (used by Agostinis et al. [51]) or (3) by packing the antigen into
lipid based colloidal systems [61]. Last but not least, skin penetration
can be enhanced (4) by microporation, either using a microneedle patch
[29, 62] or a LASER [63•, 64].
While all the above methods enhance skin penetration of allergens, it
remains to be seen to which degree each of these methods also activate
keratinocytes, which importantly interact with Langerhans cells. It may
be speculated that the different outcomes of the above methods, e.g., the
relative inefficacy of the Viaskin® chamber, may well be explained by the
assumption that hydration alone does not activate keratinocytes as much
as tape stripping or abrasion. In fact, a heavily disrupted skin barrier has
been observed to polarize the immune response toward Th1, whereas
slight skin barrier disruption rather induces a non-inflammatory Th2/
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Treg–dominated response [23]. The evidence in this area is conflicting, as
Mondoulet et al., in their mouse models of peanut allergy, find intact
skin and un-stripped skin to be crucial for efficacy and safety of im-
munotherapy [65]. In contrast, our mouse models using OVA find no
therapeutic effect if the skin was not tape stripped before allergen ap-
plication [22].
Adjuvants in EPIT represent another strategy to enhance efficacy. Al-
um is the adjuvant used in the majority of marketed vaccines today
[66]; however, it is not suitable for epicutaneous administration [67].
Thus far, cholera toxin (CT) and heat-labile enterotoxin (LT) have been
successfully used as adjuvants in epicutaneous vaccination against in-
fectious diseases of mice and humans [27••, 67, 68]. On the other hand,
imidazoquinolines (TLR7 or -8 ligands) and CpG (TLR9 ligands) are
currently being tested as adjuvants for epicutaneous vaccination against
cancer [33, 69]. Our group recently tested the immune-enhancing and
immune-modulatory potential of diphenylcyclopropenone when used as
adjuvant in EPIT [22].
Conclusion
In light of the increasing prevalence of allergic disease [70, 71], which strongly
contrasts with the low percentage of patients choosing SCIT [4, 7], research
during the next century should aim at optimization of current AIT methods in
order to increase its attractiveness. Optimization of allergen immunotherapy
should (1) deliver the allergen via a route that efficiently targets professional
APCs, (2) use optimal adjuvants, (3) avoid allergen delivery to highly
vascularized sites as to minimize systemic allergic side effects, and (4) be con-
venient for the patient, i.e., self-administrable andpainless. Epicutaneous allergy
immunotherapy holds promise in all four aspects: (1) the epidermis contains a
high number of potent APCs, (2) adjuvants can be topically administered and/
or physical or chemical trauma to keratinocytes may already act as an “physical
adjuvant”, (3) the epidermis is non-vascularized, and (4) epicutaneous ad-
ministration can be done at home and is painless.
Being afraid of needles, children would especially benefit most from a
needle-free form of AIT [72], as AIT early in the course of allergic dis-
eases has the potential to stop disease progression to asthma, which
represents a considerable health burden. Such reasoning might highlight
the development of a preventive, needle-free, patch-based allergy vaccine,
accepted as a part of the WHO recommended “early childhood” vacci-
nation program, to conquer the epidemic of the twenty-first century.
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